DNA base editing corrects common hemophilia A mutations and restores factor VIII expression in in vitro and ex vivo models

J Thromb Haemost. 2024 Aug;22(8):2171-2183. doi: 10.1016/j.jtha.2024.04.020. Epub 2024 May 7.

Abstract

Background: Replacement and nonreplacement therapies effectively control bleeding in hemophilia A (HA) but imply lifelong interventions. Authorized gene addition therapy could provide a cure but still poses questions on durability. FVIIIgene correction would definitively restore factor (F)VIII production, as shown in animal models through nuclease-mediated homologous recombination (HR). However, low efficiency and potential off-target double-strand break still limit HR translatability.

Objectives: To correct common model single point mutations leading to severe HA through the recently developed double-strand break/HR-independent base editing (BE) and prime editing (PE) approaches.

Methods: Screening for efficacy of BE/PE systems in HEK293T cells transiently expressing FVIII variants and validation at DNA (sequencing) and protein (enzyme-linked immunosorbent assay; activated partial thromboplastin time) level in stable clones. Evaluation of rescue in engineered blood outgrowth endothelial cells by lentiviral-mediated delivery of BE.

Results: Transient assays identified the best-performing BE/PE systems for each variant, with the highest rescue of FVIII expression (up to 25% of wild-type recombinant FVIII) for the p.R2166∗ and p.R2228Q mutations. In stable clones, we demonstrated that the mutation reversion on DNA (∼24%) was consistent with the rescue of FVIII secretion and activity of 20% to 30%. The lentiviral-mediated delivery of the selected BE systems was attempted in engineered blood outgrowth endothelial cells harboring the p.R2166∗ and p.R2228Q variants, which led to an appreciable and dose-dependent rescue of secreted functional FVIII.

Conclusion: Overall data provide the first proof-of-concept for effective BE/PE-mediated correction of HA-causing mutations, which encourage studies in mouse models to develop a personalized cure for large cohorts of patients through a single intervention.

Keywords: CRISPR; base/prime editors; factor VIII; gene editing; hemophilia A.

MeSH terms

  • CRISPR-Cas Systems
  • Endothelial Cells / metabolism
  • Factor VIII* / genetics
  • Factor VIII* / metabolism
  • Gene Editing* / methods
  • Genetic Therapy*
  • HEK293 Cells
  • Hemophilia A* / blood
  • Hemophilia A* / genetics
  • Hemophilia A* / therapy
  • Humans
  • Mutation
  • Point Mutation

Substances

  • Factor VIII
  • F8 protein, human